Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IRIDEX Corporation - Common Stock (NQ:IRIX)

0.7254 +0.0135 (+1.90%)
Delayed Quote Updated: 12:09 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about IRIDEX Corporation - Common Stock

< Previous 1 2 3 Next >
News headline image
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
Study reports sustained IOP reduction and reduced medication burden over 24 months 
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Completes Relocation of Manufacturing Facility to San Jose, California
Company Expects to Realize Approximately $600,000 in Annualized Cost Savings 
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Reports Second Quarter 2026 Financial Results
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Reports First Quarter 2026 Financial Results
2026 Guidance Affirmed 
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies 
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Announces Plans to Relocate Headquarters
Move expected to generate significant cost savings 
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
Demonstrating continued revenue growth, operational efficiencies and positive cash flow 
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Present at the Sidoti Year-End Virtual Investor Conference
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Reports Third Quarter 2025 Financial Results
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Reports Second Quarter 2025 Financial Results
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Reports First Quarter 2025 Financial Results
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Report First Quarter 2025 Financial Results on May 13, 2025
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Host Strategic Vision Call on April 16, 2025
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Announces Strategic Investment in the Company
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex Comments on Recent Stock Price Volatility
From IRIDEX Corporation
Via GlobeNewswire
News headline image
Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
From IRIDEX Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.